Identification of genes potentially involved in the acquisition of androgen-independent and metastatic tumor growth in an autochthonous genetically engineered house prostate cancer model

Prostate

Volumn 67, Issue 1, 2007, Pages 83-106

  Morgenbesser, Sharon D ^a   McLaren, Rajashree P ^a   Richards, Brenda ^a   Zhang, Mindy ^a   Akmaev, Viatcheslav R ^a   Winter, Scott F ^b   Mineva, Nora D ^a   Kaplan Lefko, Paula J ^b,c   Foster, Barbara A ^b,d   Cook, Brian P ^a   Dufault, Michael R ^a   Cao, Xiahong ^a   Wang, Clarence J ^a   Teicher, Beverly A ^a   Klinger, Katherine W ^a   Greenberg, Norman M ^b,e   Madden, Stephen L ^a  

^a GENZYME CORPORATION   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c AMGEN INC   (United States)

^d ROSWELL PARK CANCER INSTITUTE   (United States)

^e Fred Hutchinson Cancer Research Center   (United States)

Author keywords

Androgen independent; Expression profiling; Metastasis; Prostate cancer; TRAMP

Indexed keywords

ANDROGEN; PHOSPHOLIPASE A2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER GROWTH; CANCER MODEL; CLUSTER ANALYSIS; CONTROLLED STUDY; DNA HYBRIDIZATION; DOWN REGULATION; GENE SEQUENCE; GENETIC ENGINEERING; GENETIC TRANSCRIPTION; GENOTYPE; MALE; MALIGNANT TRANSFORMATION; METASTASIS; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; REAL TIME POLYMERASE CHAIN REACTION; SERIAL ANALYSIS OF GENE EXPRESSION; TUMOR GROWTH; VALIDATION PROCESS;

ADENOCARCINOMA; ANDROGENS; ANIMALS; DISEASE MODELS, ANIMAL; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, NEOPLASM; GENETIC ENGINEERING; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, INBRED DBA; MICE, TRANSGENIC; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROSTATIC NEOPLASMS; SPECIES SPECIFICITY;

EID: 33845741518     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.20505     Document Type: Article

References (70)

1. Nicholson B, Teodorescu D. Molecular therapeutics in prostate cancer. Histol Histopathol 2003;18:275-298.
2. Nelson PS, Clegg N, Arnold H, Ferguson C, Bonham M, White J, Hood L, Lin B. The program of androgen-responsive genes in neoplastic prostate epithelium. Proc Natl Acad Sci USA 2002;99:11890-11895.
3. Bogenrieder T, Herlyn M. Axis of evil: Molecular mechanisms of cancer metastasis. Oncogene 2003;22:6524-6536.
4. Greenberg NM, DeMayo F, Finegold MJ, Medina D, Tilley WD, Aspinall JO, Cunha GR, Donjacour AA, Marusik RJ, Rosen JM. Prostate cancer in a transgenic mouse. Proc Natl Acad Sci USA 1995;92:3439-3443.
5. Kaplan-Lefko PJ, Chen TM, Ittmann MM, Barrios RJ, Ayala GE, Huss WJ, Maddison LA, Foster BA, Greenberg NM. Pathobiology of autochthonous prostate cancer in a pre-clinical transgenic mouse model. Prostate 2003;55:219-237.
6. Gingrich JR, Barrios RJ, Kattan MW, Nahm HS, Finegold MJ, Greenberg NM. Androgen-independent prostate cancer progression in the TRAMP model. Cancer Res 1997;57:4687-4691.
7. Velculescu VE, Zhang L, Vogelstein B, Kinzler KW. Serial analysis of gene expression. Science 1995;270:484-487.
8. St. Croix B, Rago C, Velculescu VE, Traverso G, Romans KE, Montgomery E, Lal A, Riggins GJ, Lengauer C, Vogelstein B, Kinzler KW. Genes expressed in human tumor endothelium. Science 2000;289:1197-1202.
9. Mootha V, Lindgren C, Eriksson K, Subramanian A, Sihag S, Lehar J, Puigserver P, Carlsson E, Ridderstrale M, Laurila E, Houstis N, Daly M, Patterson N, Mesirov J, Golub T, Tamayo P, Spiegelman B, Lander E, Hirschhorn J, Altshuler D, Groop L. PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet 2003;34:267-273.
10. Kennedy BP, Payette P, Mudgett J, Vadas P, Pruzanski W, Kwan M, Tang C, Rancourt DE, Cromlish WA. A natural disruption of the secretory group II phospholipase A2 gene in inbred mouse strains. J Biol Chem 1995;270:22378-22385.
11. Johnson MA, Hernandez I, Wei Y, Greenberg N. Isolation and characterization of mouse probasin: An androgen-regulated protein specifically expressed in the differentiated prostate. Prostate 2000;43:255-262.
12. Wubah JA, Fischer CM, Rolfzen LN, Khalili M, Kang J, Green JE, Bieberich CJ. Ventral prostate predominant 1, a novel mouse gene expressed exclusively in the prostate. Prostate 2002;51: 21-29.
13. Umbas R, Schalken JA, Aalders TW, Carter BS, Karthaus HFM, Schaafsma HE, Debruyne FMJ, Isaacs WB. Expression of the cellular adhesion molecule E-Cadherin is reduced or absent in high-grade prostate cancer. Cancer Res 1992;52:5104-5109.
14. Gingrich JR, Barrios RJ, Morton RA, Boyce BF, DeMayo FJ, Finegold MJ, Angelopoulou R, Rosen JM, Greenberg NM. Metastatic prostate cancer in a transgenic mouse. Cancer Res 1996;56:4096-4102.
15. Chan PS, Chan LW, Xuan JW, Chin JL, Choi HL, Chan FL. In situ hybridization study of PSP94 (prostatic secretory protein of 94 amino acids) expression in human prostates. Prostate 1999;41: 99-109.
16. Nowaza M, Yomogida K, Kanno N, Nonomura N, Miki T, Okuyama A, Nishimune Y, Nozaki M. Prostate-specific transcription factor hPSE is translated only in normal prostate epithelial cells. Cancer Res 2000;60:1348-1352.
17. Birckbichler PJ, Bonner RB, Hurst RE, Bane BL, Pitha JV, Hemstreet GP. Loss of tissue transglutaminase as a biomarker for prostate adenocarcinoma. Cancer 2000;89:412-423.
18. Lee W-H, Morton RA, Epstein JI, Brooks JD, Campbell PA, Bova GS, Hsieh W-S, Isaacs WB, Nelson WG. Cytidine methylation of regulatory sequences near the pi-class glutathione S-transferase gene accompanies human prostatic carcinogenesis. Proc Natl Acad Sci USA 1994;91:11733-11737.
19. Elek J, Park KH, Narayanan R. Microarray-based expression profiling in prostate tumors. In Vivo 2000;14:173-182.
20. Chetcuti A, Margan S, Mann S, Russell P, Handelsman D, Rogers J, Dong Q. Identification of differentially expressed genes in organ-confined prostate cancer by gene expression array. Prostate 2001;47:132-140.
21. Pang ST, Dillner K, Wu X, Pousette A, Norstedt G, Flores-Morales A. Gene expression profiling of androgen deficiency predicts a pathway of prostate apoptosis that involves genes related to oxidative stress. Endocrinology 2002;143:4897-4906.
22. Strickler SM, Dansky LV, Miller MA, Seni MH, Andermann E, Spielberg SP. Genetic predisposition to phenytoin-induced birth defects. Lancet 1985;2:746-749.
23. Silverman GA, Bird PI, Carrell RW, Church FC, Coughlin PB, Gettins PG, Irving JA, Lomas DA, Luke CJ, Moyer RW, Pemberton PA, Remold-O'Donnell E, Salvesen GS, Travis J, Whisstock JC. The serpins are an expanding superfamily of structurally similar but functionally diverse proteins. Evolution, mechanism of inhibition, novel functions, and a revised nomenclature. J Biol Chem 2001;276:33293-33296.
24. Schuster JM, Longo M, Nelson PS. Differential expression of bikunin (HAI-2/PB), a proposed mediator of glioma invasion, by demethylation treatment. J Neurooncol 2003;64:219-225.
25. Morgenstern KA, Henzel WJ, Baker JB, Wong S, Pastuszyn A, Kisiel W. Isolation and characterization of an intracellular serine proteinase inhibitor from a monkey kidney epithelial cell line. J Biol Chem 1993;268:21560-21568.
26. Brand K. Cancer gene therapy with tissue inhibitors of metalloproteinases (TIMPs). Curr Gene Ther 2002;2:255-271.
27. Sewak S, Chachoua A, Hamilton A, Taneja S, Lee J, Utate M, Sorich J, Muggia FM. A phase I study of paclitaxel, estramustine phosphate and vinorelbine (Pacl-E-Vin) in advanced malignancies: Triple tubulin targeting. Anticancer Drugs 2003;14:67-72.
28. Van Brussel JP, Jan Van Steenbrugge G, Van Krimpen C, Bogdanowicz JF, Van Der Kwast TH, Schröder FH, Mickisch GH. Expression of multidrug resistance related proteins and proliferative activity is increased in advanced clinical prostate cancer. J Urol 2001;165:130-135.
29. Krajewska M, Krajewska S, Banares S, Huang X, Turner B, Bubendorf L, Kallioniemi O-P, Shabaik A, Vitiello A, Peehl D, Gao G-J, Reed JC. Elevated expression of inhibitor of apoptosis proteins in prostate cancer. Clin Cancer Res 2003;9:4914-4925.
30. Muñoz E, Gómez F, Paz JI, Casado I, Silva JM, Corcuera MT, Alonso MJ. Ki-67 immunolabeling in pre-malignant lesions and carcinoma of the prostate. Histological correlation and prognostic evaluation. Eur J Histochem 2003;47:123-128.
31. Konishi N, Nakamura M, Nakaoka S, Hiasa Y, Cho M, Uemura H, Hirao Y, Muramatsu T, Kadomatsu K. Immunohistochemical analysis of midkine expression in human prostate carcinoma. Oncology 1999;57:253-257.
32. Hansson J, Abrahamsson P-A. Neuroendocrine pathogenesis in adenocarcinoma of the prostate. Ann Oncol 2001;12:S145-S152.
33. McEleny KR, Watson R, Coffey RN, O'Neill AJ, Fitzpatrick JM. Inhibitors of apoptosis proteins in prostate cancer cell lines. Prostate 2002;51:133-140.
34. Friedrich B, Gronberg H, Landstrom M, Gullberg M, Bergh A. Differentiation-stage specific expression of oncoprotein 18 in human and rat prostatic adenocarcinoma. Prostate 1995;27:102-109.
35. Ranganathan S, Salazar H, Benetatos CA, Hudes GR. Immunohistochemical analysis of beta-tubulin isotypes in human prostate carcinoma and benign prostatic hypertrophy. Prostate 1997;30:263-268.
36. Waghray A, Feroze F, Schober MS, Yao F, Wood C, Puravs E, Krause M, Hanash S, Chen YQ. Identification of androgen-regulated genes in the prostate cancer cell line LNCaP by serial analysis of gene expression and proteomic analysis. Proteomics 2001;1:1327-1338.
37. Hoosein NM, Martin KJ, Abdul M, Logothetis CJ, Kaddurah-Daouk R. Antiproliferative effects of cyclocreatine on human prostatic carcinoma cells. Anticancer Res 1995;15:1339-1342.
38. Porkka KP, Visakorpi T. Detection of differentially expressed genes in prostate cancer by combining suppression subtractive hybridization and cDNA library array. J Pathol 2001;193:73-79.
39. Garde SV, Basrur VS, Li L, Finkelman MA, Krishan A, Wellham L, Ben-Josef E, Haddad M, Taylor JD, Porter AT, Tang DG. Prostate secretory protein (PSP94) suppresses the growth of androgen-independent prostate cancer cell line (PC3) and xenografts by inducing apoptosis. Prostate 1999;38:118-125.
40. Gu Z, Thomas G, Yamashiro J, Shintaku IP, Dorey F, Raitano A, Witte ON, Said JW, Loda M, Reiter RE. Prostate stem cell antigen (PSCA) expression increases with high gleason score, advanced stage and bone metastasis in prostate cancer. Oncogene 2000;19:1288-1296.
41. Dubey P, Wu H, Reiter RE, Witte ON. Alternative pathways to prostate carcinoma activate prostate stem cell antigen expression. Cancer Res 2001;61:3256-3261.
42. Graff JR, Konicek BW, Deddens JA, Chedid M, Hurst BM, Colligan B, Neubauer BL, Carter HW, Carter JH. Expression of group lia secretory phospholipase A2 increases with prostate tumor grade. Clin Cancer Res 2001;7:3857-3861.
43. Huss WJ, Hanrahan CF, Barrios RJ, Simons JW, Greenberg NM. Angiogenesis and prostate cancer: Identification of a molecular progression switch. Cancer Res 2001;61:2736-2743.
44. Zeng Q, Dong J-M, Guo K, Li J, Tan H-X, Koh V, Pallen CJ, Manser E, Hong W. PRL-3 and PRL-1 promote cell migration, invasion, and metastasis. Cancer Res 2003;63:2716-2722.
45. Gittes RF. Carcinoma of the prostate. N Engl J Med 1991;324:236-245.
46. Gérard AC, Daumerie C, Mestdagh C, Gohy S, De Burbure C, Costagliola S, Miot F, Nollevaux MC, Denef JF, Rahier J, Franc B, De Vijlder JJ, Colin IM, Many MC. Correlation between the loss of thyroglobulin iodination and the expression of thyroid-specific proteins involved in iodine metabolism in thyroid carcinomas. J Clin Endocrinol Metab 2003;88:4977-4983.
47. Gounari F, Signoretti S, Bronson R, Klein L, Sellers WR, Kum J, Siermann A, Taketo MM, von Boehmer H, Khazaie K. Stabilization of beta-catenin induces lesions reminiscent of prostatic intraepithelial neoplasia, but terminal squamous transdifferentiation of other secretory epithelia. Oncogene 2002;21:4099-4107.
48. Gerke V, Moss SE. Annexins: From structure to function. Physiol Rev 2002;82:331-371.
49. Martin TA, Harrison G, Mansel RE, Jiang WG. The role of the CD44/ezrin complex in cancer metastasis. Crit Rev Oncol Hematol 2003;46:165-186.
50. Tokunou M, Niki T, Saitoh Y, Imamura H, Sakamoto M, Hirohashi S. Altered expression of the ERM proteins in lung adenocarcinoma. Lab Invest 2000;80:1643-1650.
51. Schindelmann S, Windisch J, Grundmann R, Kreienberg R, Zeillinger R, Deissler H. Expression profiling of mammary carcinoma cell lines: Correlation of in vitro invasiveness with expression of CD24. Tumour Biol 2002;23:139-145.
52. Thompson DA, Weigel RJ. hAG-2, the human homologue of the Xenopus laevis cement gland gene XAG-2, is coexpressed with estrogen receptor in breast cancer cell lines. Biochem Biophys Res Commun 1998;251:111-116.
53. Klagsbrun M, Takashima S, Mamluk R. The role of neuropilin in vascular and tumor biology. Adv Exp Med Biol 2002;515: 33-48.
54. Latil A, Bieche I, Pesche S, Valeri A, Fournier G, Cussenot O, Lidereau R. VEGF overexpression in clinically localized prostate tumors and neuropilin-1 overexpression in metastatic forms. Int J Cancer 2000;89:167-171.
55. Hollingsworth MA, Swanson BJ. Mucins in cancer: Protection and control of the cell surface. Nat Rev 2004;4:45-60.
56. Hosoda A, Kimata Y, Tsuru A, Kohno K. JPDI, a novel endoplasmic reticulum-resident protein containing both a BiP-interacting J-domain and thioredoxin-like motifs. J Biol Chem 2003;278:2669-2676.
57. Cunnea PM, Miranda-Vizuete A, Bertoli G, Simmen T, Damdimopoulos AE, Hermann S, Leinonen S, Huikko MP, Gustafsson JA, Sitia R, Spyrou G. ERdj5, an endoplasmic reticulum (ER)-resident protein containing DnaJ and thioredoxin domains, is expressed in secretory cells or following ER stress. J Biol Chem 2003;278:1059-1066.
58. Bossone SA, Asselin C, Patel AJ, Marcu KB. MAZ, a zinc finger protein, binds to c-MYC and C2 gene sequences regulating transcriptional initiation and termination. Proc Natl Acad Sci USA 1992;89:7452-7456.
59. Karan D, Lin MF, Johansson SL, Batra SK. Current status of the molecular genetics of human prostatic adenocarcinomas. Int J Cancer 2003;103:285-293.
60. Dube JY, Chapdelaine P, Trahan PL, Deperthes D, Frenette G, Tremblay RR. Abundant cysteine-rich protein-1 is localized in the stromal compartment of the human prostate. Arch Androl 1998;40:109-115.
61. Weiskirchen R, Gunther K. The CRP/MLP/TLP family of LIM domain proteins: Acting by connecting. BioEssays 2003;25: 152-162.
62. Weiss MJ, Orkin SH. GATA transcription factors: Key regulators of hematopoiesis. Exp Hematol 1995;23:99-107.
63. Sharpe JC, Abel PD, Gilbertson JA, Brawn P, Foster CS. Modulated expression of human leucocyte antigen class I and class II determinants in hyperplastic and malignant human prostatic epithelium. Br J Urol 1994;74:609-616.
64. Kutzleb C, Sanders G, Yamamoto R, Wang X, Lichte B, Petrasch-Parwez E, Kilimann MW. Paralemmin, a prenyl-palmitoyl-anchored phosphoprotein abundant in neurons and implicated in plasma membrane dynamics and cell process formation. J Cell Biol 1998;143:795-813.
65. Jiang J, Neubauer BL, Graff JR, Chedid M, Thomas JE, Roehm NW, Zhang S, Eckert GJ, Koch MO, Eble JN, Cheng L. Expression of group IIA secretory phospholipase A2 is elevated in prostatic intraepithelial neoplasia and adenocarcinoma. Am J Pathol 2002;160:667-671.
66. Ablin RJ, Shaw MW. Prostaglandin modulation of prostate tumor growth and metastases. Anticancer Res 1986;6:327-328.
67. Rose D, Connolly J. Effects of fatty acids and eicosanoid synthesis inhibitors on the growth of two human prostate cancer cell lines. Prostate 1991;18:243-254.
68. Gingrich JR, Barrios RJ, Foster BA, Greenberg NM. Pathologic progression of autochthonous prostate cancer in the TRAMP model. Prostate Cancer Prostatic Dis 1999;2:70-75.
69. Wang M, Liu YE, Greene J, Sheng S, Fuchs A, Rosen EM, Shi YE. Inhibition of tumor growth and metastasis of human breast cancer cells transfected with tissue inhibitor of metalloproteinase 4. Oncogene 1997;14:2767-2774.
70. Groft LL, Muzik H, Rewcastle NB, Johnston RN, Knäuper V, Lafleur MA, Forsyth PA, Edwards DR. Differential expression and localization of TIMP-1 and TIMP-4 in human gliomas. Br J Cancer 2001;85:55-63.